AI accountability, faster FDA pathways, rare disease CMC review, and next-gen GLP-1 formulation lead this week’s PharmTech roundup.
News|Articles|November 2, 2017
- Pharmaceutical Technology-11-02-2017
- Volume 41
- Issue 11
Methods for Identifying Out-of-Trend Data in Analysis of Stability Measurements–Part I: Regression Control Chart
Author(s)Sándor Kemény, Máté Mihalovits
In Part I of this article series, the regression control chart method for identifying out-of-trend data in pharmaceutical stability studies is investigated, and an improved approach is suggested.
Advertisement
Abstract
The regulation of pharmaceutical stability studies still lacks universally accepted techniques regarding the identification of out-of-trend data. Three methods have been suggested for identifying out-of-trend data in pharmaceutical stability studies: the regression control chart, the by-time-point method, and the slope control chart. In Part I of this article series, the regression control chart method is investigated, and an improved approach is suggested. The method is illustrated using realistic data. In Part II, the by-time-point method and the multivariate control chart method will be discussed.
Peer-Review Article
Submitted: March 22, 2017
Accepted: June 27, 2017
About the Authors
Máté Mihalovits is a PhD student, mihalovits@mail.bme.hu; and Sándor Kemény* is an emeritus professor, Tel.: +36 309936307, kemeny@mail.bme.hu, both at Budapest University of Technology and Economics, Faculty of Chemical Technology and Biotechnology, Department of Chemical and Environmental Process Engineering Hungary, 1111. Budapest, Műegyetem rakpart 3.
* To whom all correspondence should be addressed.
Article Details
Pharmaceutical Technology
Vol. 41, No. 11
November 2017
Pages: 46–53
Citation:
When referring to this article, please cite it as M. Mihalovits and S. Kemény, "Methods for Identifying Out-of-Trend Data in Analysis of Stability Measurements–Part I: Regression Control Chart," Pharmaceutical Technology 41 (11) 2017.
Articles in this issue
almost 9 years ago
Establishing an Effective Data Governance Systemalmost 9 years ago
ODTs Dissolve Drug Administration Challengesalmost 9 years ago
Reducing Medication Errorsalmost 9 years ago
Patient Centricity Takes Center Stagealmost 9 years ago
Europe Leads the Way in Continuous Manufacturingalmost 9 years ago
Change Control for Standard Operating Proceduresalmost 9 years ago
CDMO Acquisitions Build Strategic Supplier Basealmost 9 years ago
A Revised Aseptic Risk Assessment and Mitigation Methodologyalmost 9 years ago
FDA Overhauls Inspection Process and Field Operationsalmost 9 years ago
Awards Recognize Industry ContributionsAdvertisement
Related to this article
Nate Edwards of Arya Consulting moderates a discussion with Elisabeth Gardiner of Tevard Biosciences and Donny Xu of the RTW Institute about rare disease treatment development and navigating the FDA’s Rare Pediatric Disease Priority Review Voucher Program.
This article examines how modern automation platforms create the digital foundation required for Pharma 4.0 by integrating manufacturing systems, centralized data management, Industrial Internet of Things connectivity, electronic batch production records, and AI-driven analytics.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Germany’s Medical Biotechnology Sector is Flourishing
2
MASH and Cardiomyopathy Targets: Why AstraZeneca Chose insitro’s AI
3
Formulation Strategies for Next-Generation Multiagonists
4
First-in-Human Trial Speed: Why FDA Trails China
5